At the news
? NEUTRALIMPACT 2/10 SC 13G/A filed Nov 6, 2026 at 10:58 ET
T. Rowe Price Investment Management filed an amended Schedule 13G for Cabaletta Bio, reporting beneficial ownership of 17,250,098 shares (8.0% of common stock) as of September 30, 2026. This is a routine passive stake update by a large asset manager; no prior T. Rowe Price 13G for CABA is in the provided context for comparison, so the direction of change is unknown. The filing has no material directional impact.
- T. Rowe Price Investment Management reported beneficial ownership of 17,250,098 shares of Cabaletta Bio common stock as of September 30, 2026
- The stake represents 8.0% of the outstanding common stock
- The filing is an amendment to Schedule 13G, indicating passive investment intent
- No prior T. Rowe Price 13G for CABA is in the provided context, so the direction of change from the previous filing is unknown
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access